ATE496937T1 - Immunogene peptidzusammensetzung zur prävention und behandlung der alzheimer-krankheit - Google Patents

Immunogene peptidzusammensetzung zur prävention und behandlung der alzheimer-krankheit

Info

Publication number
ATE496937T1
ATE496937T1 AT09168110T AT09168110T ATE496937T1 AT E496937 T1 ATE496937 T1 AT E496937T1 AT 09168110 T AT09168110 T AT 09168110T AT 09168110 T AT09168110 T AT 09168110T AT E496937 T1 ATE496937 T1 AT E496937T1
Authority
AT
Austria
Prior art keywords
peptide
alzheimer
disease
prevention
treatment
Prior art date
Application number
AT09168110T
Other languages
English (en)
Inventor
Chang Yi Wang
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Application granted granted Critical
Publication of ATE496937T1 publication Critical patent/ATE496937T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT09168110T 2001-05-25 2002-04-02 Immunogene peptidzusammensetzung zur prävention und behandlung der alzheimer-krankheit ATE496937T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/865,294 US6906169B2 (en) 2001-05-25 2001-05-25 Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide

Publications (1)

Publication Number Publication Date
ATE496937T1 true ATE496937T1 (de) 2011-02-15

Family

ID=25345158

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02731223T ATE474000T1 (de) 2001-05-25 2002-04-02 Immunogene peptidzusammensetzung zur prävention und behandlung der alzheimer-krankheit
AT09168110T ATE496937T1 (de) 2001-05-25 2002-04-02 Immunogene peptidzusammensetzung zur prävention und behandlung der alzheimer-krankheit

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02731223T ATE474000T1 (de) 2001-05-25 2002-04-02 Immunogene peptidzusammensetzung zur prävention und behandlung der alzheimer-krankheit

Country Status (15)

Country Link
US (3) US6906169B2 (de)
EP (2) EP2123671B1 (de)
JP (3) JP4440544B2 (de)
CN (2) CN101372511B (de)
AT (2) ATE474000T1 (de)
AU (2) AU2002303211B2 (de)
BR (1) BRPI0210010B8 (de)
CA (2) CA2448171A1 (de)
DE (2) DE60237044D1 (de)
DK (2) DK2123671T3 (de)
ES (2) ES2348975T3 (de)
MX (1) MXPA03010631A (de)
TW (1) TWI252233B (de)
WO (1) WO2002096350A2 (de)
ZA (1) ZA200308767B (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20050059591A1 (en) * 1998-04-07 2005-03-17 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
WO2001062284A2 (en) * 2000-02-21 2001-08-30 Pharmexa A/S Novel method for down-regulation of amyloid
HRP20020721B1 (en) * 2000-02-21 2012-04-30 H. Lundbeck A/S Novel method for down-regulation of amyloid
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
EP1572894B1 (de) * 2001-11-21 2016-04-13 New York University Zu amyloid-beta, prionprotein, amylin, alpha-synuclein oder polyglutaminwiederholungen homologe synthetische immunogene, jedoch keine ablagerungen bildende polypeptide und peptide zur induzierung einer immunreaktion dagegen
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
US20040001848A1 (en) * 2002-03-01 2004-01-01 Szu-Yi Chou Method of producing disease-specific antigens
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
KR100994748B1 (ko) * 2002-04-19 2010-11-17 더 가버닝 카운실 오브 더 유니버시티 오브 토론토 알쯔하이머병의 치료를 위한 면역학적 방법 및 조성물
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
JP4888876B2 (ja) 2003-06-13 2012-02-29 田平 武 アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター
EP1515158B1 (de) * 2003-09-09 2013-07-17 Esaote S.p.A. Ultraschall-Bilderzeugungsverfahren mit Kontrastmittel-Anwesenheit in dem Aufnahmeobjekt
SI2336147T1 (sl) 2003-12-17 2014-08-29 Janssen Alzheimer Immunotherapy Konjugati nosilcev a beta imunogenih peptidov in postopki izdelave istih
JP2007522119A (ja) * 2004-01-28 2007-08-09 キュリックス エーピーエス アミロイド関連疾患用ワクチンとしてのアミロイドタンパク質のコンジュゲート
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
GB0427267D0 (en) * 2004-12-13 2005-01-12 Maria Teresa De Magistris Peptide adjuvants
EP1838348B1 (de) * 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
US20060257396A1 (en) * 2004-12-15 2006-11-16 Jacobsen Jack S Abeta antibodies for use in improving cognition
ES2396555T3 (es) * 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
CA2633399C (en) * 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
CN101421299A (zh) 2006-02-22 2009-04-29 株式会社林原生物化学研究所 用于诱导产生抗淀粉样β肽抗体的肽疫苗
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CN101058608B (zh) * 2006-04-21 2011-02-23 杜如昱 人类抗Aβ1-32淀粉样蛋白抗体、其纯化方法及用途
US8357781B2 (en) 2006-06-01 2013-01-22 Janssen Alzheimer Immunotherapy Neuroactive fragments of APP
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
WO2008131298A2 (en) * 2007-04-18 2008-10-30 Elan Pharma International Limited Prevention and treatment of cerebral amyloid angiopathy
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8106015B2 (en) * 2007-04-20 2012-01-31 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method for enhancing immune response with peptide
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2106802A1 (de) 2008-04-02 2009-10-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Modifizierte Peptide als synthetische Impfungen bei Amyloid-bedingten Krankheiten
US9498522B2 (en) 2008-08-07 2016-11-22 Mercia Pharma Inc. Immunotherapeutic compositions for the treatment of alzheimer'S disease
WO2010080188A2 (en) * 2008-10-14 2010-07-15 The Regents Of The University Of Michigan Epitope targeted anthrax vaccine
US8512709B2 (en) 2008-10-16 2013-08-20 The Chemo-Sero-Therapeutic Research Institue Modified amyloid β peptide
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
DE102008037564A1 (de) * 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
EP4218794A3 (de) 2009-06-10 2023-09-13 New York University Immunologisches targeting pathologischer tau-proteine
US20110221240A1 (en) * 2010-03-11 2011-09-15 Ziming Shen Compact children's table and stool set
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9932372B2 (en) 2010-07-08 2018-04-03 United Biomedical, Inc. Designer peptide-based PCV2 vaccine
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
CN102775478B (zh) * 2012-08-10 2013-06-19 申联生物医药（上海）有限公司 口蹄疫病毒抗原多肽及疫苗
EP2887955B1 (de) 2012-08-21 2020-08-19 Institute for Molecular Medicine, Inc. Zusammensetzungen und verfahren mit erkrankungen im zusammenhang mit ablagerungen von amyloid, tau und alpha-synuklein
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
EP3027205A4 (de) 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Impfstoffformulierungen zur induzierung einer th2-immunantwort
TWI609026B (zh) * 2014-03-14 2017-12-21 美國聯合生物醫學公司 抑制與免疫治療阿茲海默型癡呆的胜肽疫苗
JP2021508672A (ja) * 2017-06-16 2021-03-11 ユナイテッド ニューロサイエンスＵｎｉｔｅｄ Ｎｅｕｒｏｓｃｉｅｎｃｅ シヌクレイノパチーの治療のためのアルファ−シヌクレインタンパク質のｃ末端からのペプチド免疫原及びその製剤
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
JP2021508673A (ja) * 2017-10-27 2021-03-11 ユナイテッド ニューロサイエンスＵｎｉｔｅｄ Ｎｅｕｒｏｓｃｉｅｎｃｅ タウペプチド免疫原構築物
KR20240110105A (ko) * 2017-12-31 2024-07-12 유나이티드 바이오메디칼 인크. Ige 매개 알레르기 질환의 치료를 위한 막 결합 ige를 표적하는 펩티드 면역원 및 이의 제제
JP2021523127A (ja) * 2018-05-04 2021-09-02 ユービーアイ アイピー ホールディングスＵｂｉ Ｉｐ Ｈｏｌｄｉｎｇｓ 限られたｔ細胞炎症反応で標的抗体産生を促進する人工的な無差別ｔヘルパー細胞エピトープ
CA3114657A1 (en) * 2018-10-01 2020-04-09 United Neuroscience Peptide immunogen constructs directed against dipeptide repeat proteins from c9orf72
MX2021007446A (es) * 2018-12-19 2021-09-08 United Biomedical Inc Epítopos artificiales promiscuos de linfocitos t colaboradores como estimuladores inmunes para inmunógenos peptídicos sintéticos.
MX2021008035A (es) * 2018-12-31 2021-12-10 United Neuroscience Ltd Inmunógenos peptídicos dirigidos al péptido relacionado con el gen de la calcitonina (cgrp) y sus formulaciones para la prevención y el tratamiento de la migraña.
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
CN110684122B (zh) * 2019-10-29 2021-03-02 中国人民解放军军事科学院军事医学研究院 重组Tau表位嵌合多聚体抗原、其制备方法和应用
AU2021276401A1 (en) * 2020-05-19 2022-12-15 Othair Prothena Limited Multi-epitope vaccine for the treatment of Alzheimer's disease
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
WO2022060488A1 (en) * 2020-09-18 2022-03-24 Othair Prothena Limited Multiepitope vaccine for the treatment of alzheimer's disease
US12537072B1 (en) 2021-05-27 2026-01-27 Amazon Technologies, Inc. Immunogenic response prediction based on major histocompatibility complex (MHC) data
US20220383996A1 (en) * 2021-05-27 2022-12-01 Amazon Technologies, Inc. Assigning peptides to peptide groups for vaccine development
CN113603773B (zh) * 2021-08-17 2023-05-09 中国医科大学附属第一医院 靶向淀粉样蛋白的单克隆抗体7b8、分泌该抗体的杂交瘤细胞株及应用
KR20240055785A (ko) * 2021-09-01 2024-04-29 백시니티, 인크. 시누클레인병증의 방지 및 치료 방법
CN117327168B (zh) * 2022-06-24 2026-06-19 厦门大学 B2M-GluN1封闭肽、其药物组合物及用途
CN116063447B (zh) * 2022-09-13 2023-11-03 北京湃德智健科技有限公司 用于检测adap自身抗体的抗原多肽及其应用
TW202438516A (zh) * 2023-01-26 2024-10-01 美商瓦辛尼帝股份有限公司 TAU及β類澱粉肽免疫原組合物及相關方法
CN122381140A (zh) * 2026-06-15 2026-07-14 鲁东大学 一种具有酪氨酸酶抑制活性及抗氧化活性的花叶滇苦菊肽及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
JP2980677B2 (ja) 1990-04-27 1999-11-22 マクマイケル，ジョン 不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物
EP0683234B2 (de) * 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US5955317A (en) * 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
ES2180576T3 (es) * 1993-04-27 2003-02-16 United Biomedical Inc Construcciones peptidicas de lhrh inmunogenicas y estimuladores de inmunidad universales sinteticos para vacunas.
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
WO1994028412A1 (en) * 1993-05-28 1994-12-08 The Miriam Hospital Composition and method for in vivo imaging of amyloid deposits
EP0725838A4 (de) 1993-10-26 1997-02-26 United Biomedical Inc Strukturierte synthetische antigenbanken als diagnostika, impfstoffe und therapeutische mittel
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
JP2003509020A (ja) * 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
EP1237930B1 (de) * 1999-12-08 2006-11-08 Intellect Neurosciences, Inc. Schimärische amyloid-beta peptide
US20030165481A1 (en) 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide

Also Published As

Publication number Publication date
WO2002096350A3 (en) 2004-11-11
ES2348975T3 (es) 2010-12-20
US20110070255A1 (en) 2011-03-24
AU2008202270B2 (en) 2010-06-17
ATE474000T1 (de) 2010-07-15
CA2665748A1 (en) 2002-12-05
JP4440544B2 (ja) 2010-03-24
EP1497313A2 (de) 2005-01-19
WO2002096350A2 (en) 2002-12-05
CA2448171A1 (en) 2002-12-05
BR0210010A (pt) 2005-10-25
US8232373B2 (en) 2012-07-31
EP2123671B1 (de) 2011-01-26
DK1497313T3 (da) 2010-10-25
AU2002303211B2 (en) 2008-02-28
JP2009221213A (ja) 2009-10-01
BRPI0210010B1 (pt) 2018-03-20
DE60237044D1 (de) 2010-08-26
HK1068215A1 (en) 2005-04-22
CN1568329B (zh) 2013-07-17
DK2123671T3 (da) 2011-05-02
JP5300592B2 (ja) 2013-09-25
EP2123671A1 (de) 2009-11-25
US20030068325A1 (en) 2003-04-10
ES2360465T3 (es) 2011-06-06
JP2009227683A (ja) 2009-10-08
JP2005506311A (ja) 2005-03-03
HK1127898A1 (en) 2009-10-09
TWI252233B (en) 2006-04-01
JP5300593B2 (ja) 2013-09-25
CA2665748C (en) 2014-01-21
EP1497313A4 (de) 2005-11-16
US6906169B2 (en) 2005-06-14
US20040247612A1 (en) 2004-12-09
EP1497313B1 (de) 2010-07-14
CN1568329A (zh) 2005-01-19
MXPA03010631A (es) 2004-09-13
ZA200308767B (en) 2005-09-28
US7951909B2 (en) 2011-05-31
DE60239093D1 (de) 2011-03-10
CN101372511B (zh) 2012-12-26
AU2008202270A1 (en) 2008-06-12
CN101372511A (zh) 2009-02-25
BRPI0210010B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
DE60237044D1 (de) Immunogene peptidzusammensetzung zur prävention und behandlung der alzheimer-krankheit
AU2006326283B2 (en) Therapeutic vaccine
IL164643A (en) Peptides, immunogenic compositions containing them and use thereof for the preparation of medicaments for the treatment of alzheimer's disease
NO20022531L (no) Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
NO20100264L (no) Forhindring og behandling av amyloidogen sykdom
ATE369380T1 (de) Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
ATE535252T1 (de) Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit
EP1409654A4 (de) Immunologische kontrolle des beta-amyloid gehaltes in vivo
BR0212999A (pt) novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
ATE364623T1 (de) Peptid zur diagnose und therapie der alzheimer- demenz
EP1701968A2 (de) Immunogene peptid-träger-konjugate und verfahren zu deren herstellung
ATE456378T1 (de) Behandlung und verhütung von neoplasmatischen und infektiösen erkrankungen mit hitzeschock / stress proteinen
HUP0303173A2 (hu) Csökkent immunogenitású, módosított anti-EGFR-ellenanyagok
WO2001053457A3 (en) Vaccines against neurodegenerative disorders

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2123671

Country of ref document: EP